ENSG00000196588 |
|
prostate adenocarcinoma |
sequence_alteration |
5.708% (83/1454) |
1 entry |
ENSG00000196588 |
|
esophageal adenocarcinoma |
sequence_alteration |
10.05% (44/438) |
1 entry |
ENSG00000196588 |
|
melanoma |
sequence_alteration |
12.87% (13/101) |
2 entries |
ENSG00000196588 |
|
breast ductal adenocarcinoma |
sequence_alteration |
13.18% (77/584) |
1 entry |
ENSG00000196588 |
|
melanoma |
conservative_inframe_deletion |
12.87% (13/101) |
1 entry |
ENSG00000196588 |
|
pancreatic ductal adenocarcinoma |
sequence_alteration |
5.56% (70/1259) |
1 entry |
ENSG00000196588 |
|
melanoma |
missense_variant |
12.87% (13/101) |
2 entries |
ENSG00000196588 |
|
colon adenocarcinoma |
missense_variant |
2.078% (15/722) |
3 entries |
ENSG00000196588 |
|
oral squamous cell carcinoma |
missense_variant |
2.427% (5/206) |
2 entries |
ENSG00000196588 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
0.8915% (6/673) |
1 entry |
ENSG00000196588 |
|
bladder carcinoma |
missense_variant |
1.622% (9/555) |
1 entry |
ENSG00000196588 |
|
lung adenocarcinoma |
missense_variant |
1.148% (14/1220) |
4 entries |
ENSG00000196588 |
|
colorectal adenocarcinoma |
frameshift_variant |
4.394% (50/1138) |
1 entry |
ENSG00000196588 |
|
acute myeloid leukemia |
sequence_alteration |
1.544% (14/907) |
1 entry |
ENSG00000196588 |
|
chronic lymphocytic leukemia |
missense_variant |
1.802% (16/888) |
1 entry |
ENSG00000196588 |
|
lung adenocarcinoma |
sequence_alteration |
1.148% (14/1220) |
6 entries |
ENSG00000196588 |
|
prostate carcinoma |
sequence_alteration |
2.686% (13/484) |
3 entries |
ENSG00000196588 |
|
colon adenocarcinoma |
frameshift_variant |
2.078% (15/722) |
2 entries |
ENSG00000196588 |
|
embryonal rhabdomyosarcoma |
sequence_alteration |
2.632% (2/76) |
1 entry |
ENSG00000196588 |
|
gastric adenocarcinoma |
sequence_alteration |
2.509% (14/558) |
1 entry |
ENSG00000196588 |
|
chronic lymphocytic leukemia |
sequence_alteration |
1.802% (16/888) |
2 entries |
ENSG00000196588 |
|
skin melanoma |
sequence_alteration |
2.068% (20/967) |
3 entries |
ENSG00000196588 |
|
colon adenocarcinoma |
sequence_alteration |
2.078% (15/722) |
5 entries |
ENSG00000196588 |
|
melanoma |
frameshift_variant |
12.87% (13/101) |
1 entry |
ENSG00000196588 |
|
hepatocellular carcinoma |
sequence_alteration |
1.667% (15/900) |
1 entry |
ENSG00000196588 |
|
esophageal squamous cell carcinoma |
missense_variant |
0.8889% (6/675) |
3 entries |
ENSG00000196588 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
0.6369% (4/628) |
2 entries |
ENSG00000196588 |
|
skin melanoma |
missense_variant |
2.068% (20/967) |
3 entries |
ENSG00000196588 |
|
female breast carcinoma |
sequence_alteration |
1.79% (7/391) |
2 entries |
ENSG00000196588 |
|
squamous cell lung carcinoma |
sequence_alteration |
1.212% (10/825) |
1 entry |
ENSG00000196588 |
|
colorectal adenocarcinoma |
missense_variant |
4.394% (50/1138) |
4 entries |
ENSG00000196588 |
|
gastric intestinal type adenocarcinoma |
sequence_alteration |
2.353% (2/85) |
1 entry |
ENSG00000196588 |
|
embryonal rhabdomyosarcoma |
missense_variant |
2.632% (2/76) |
1 entry |
ENSG00000196588 |
|
gastric adenocarcinoma |
missense_variant |
2.509% (14/558) |
1 entry |
ENSG00000196588 |
|
bladder carcinoma |
sequence_alteration |
1.622% (9/555) |
1 entry |
ENSG00000196588 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.6369% (4/628) |
1 entry |
ENSG00000196588 |
|
clear cell renal carcinoma |
missense_variant |
0.6074% (8/1317) |
1 entry |
ENSG00000196588 |
|
brain glioblastoma |
missense_variant |
0.324% (3/926) |
1 entry |
ENSG00000196588 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000196588 |
|
hepatocellular carcinoma |
missense_variant |
1.667% (15/900) |
1 entry |
ENSG00000196588 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
5.56% (70/1259) |
1 entry |
ENSG00000196588 |
|
clear cell renal carcinoma |
sequence_alteration |
0.6074% (8/1317) |
2 entries |
ENSG00000196588 |
|
anaplastic astrocytoma |
sequence_alteration |
4.545% (2/44) |
1 entry |
ENSG00000196588 |
|
colorectal adenocarcinoma |
sequence_alteration |
4.394% (50/1138) |
4 entries |
ENSG00000196588 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
0.8889% (6/675) |
4 entries |
ENSG00000196588 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.8915% (6/673) |
1 entry |
ENSG00000196588 |
|
papillary renal cell carcinoma |
sequence_alteration |
1.201% (4/333) |
1 entry |
ENSG00000196588 |
|
oral squamous cell carcinoma |
sequence_alteration |
2.427% (5/206) |
3 entries |
ENSG00000196588 |
|
brain glioblastoma |
sequence_alteration |
0.324% (3/926) |
2 entries |
ENSG00000196588 |
|
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
1.198% (2/167) |
1 entry |
ENSG00000196588 |
|
ganglioneuroblastoma |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000196588 |
|
prostate carcinoma |
missense_variant |
2.686% (13/484) |
1 entry |
ENSG00000196588 |
|
head and neck squamous cell carcinoma |
frameshift_variant |
0.6369% (4/628) |
1 entry |
ENSG00000196588 |
|
osteosarcoma |
sequence_alteration |
0.8621% (1/116) |
1 entry |
ENSG00000196588 |
|
lung adenocarcinoma |
frameshift_variant |
1.148% (14/1220) |
1 entry |
ENSG00000196588 |
|
lung adenocarcinoma |
stop_gained |
1.148% (14/1220) |
1 entry |
ENSG00000196588 |
|
Mantle cell lymphoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000196588 |
|
bile duct adenocarcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000196588 |
|
large cell lung carcinoma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000196588 |
|
Mantle cell lymphoma |
sequence_alteration |
2.439% (1/41) |
1 entry |
ENSG00000196588 |
|
ovarian serous adenocarcinoma |
frameshift_variant |
0.8915% (6/673) |
1 entry |
ENSG00000196588 |
|
small cell lung carcinoma |
missense_variant |
0.3106% (1/322) |
1 entry |
ENSG00000196588 |
|
renal cell carcinoma |
sequence_alteration |
9.091% (1/11) |
1 entry |
ENSG00000196588 |
|
acute lymphoblastic leukemia |
missense_variant |
0.3115% (1/321) |
1 entry |
ENSG00000196588 |
|
large cell lung carcinoma |
sequence_alteration |
5.556% (1/18) |
1 entry |
ENSG00000196588 |
|
non-small cell lung carcinoma |
sequence_alteration |
1.613% (1/62) |
1 entry |
ENSG00000196588 |
|
female breast carcinoma |
missense_variant |
1.79% (7/391) |
1 entry |
ENSG00000196588 |
|
renal cell carcinoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000196588 |
|
alveolar rhabdomyosarcoma |
missense_variant |
1.695% (1/59) |
1 entry |
ENSG00000196588 |
|
adrenocortical adenoma |
sequence_alteration |
2.5% (1/40) |
1 entry |
ENSG00000196588 |
|
bile duct adenocarcinoma |
sequence_alteration |
0.5291% (1/189) |
1 entry |
ENSG00000196588 |
|
basal cell carcinoma |
missense_variant |
1.724% (1/58) |
1 entry |
ENSG00000196588 |
|
acute lymphoblastic leukemia |
sequence_alteration |
0.3115% (1/321) |
1 entry |
ENSG00000196588 |
|
adrenocortical adenoma |
missense_variant |
2.5% (1/40) |
1 entry |
ENSG00000196588 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.198% (2/167) |
1 entry |
ENSG00000196588 |
|
alveolar rhabdomyosarcoma |
sequence_alteration |
1.695% (1/59) |
1 entry |
ENSG00000196588 |
|
papillary renal cell carcinoma |
frameshift_variant |
1.201% (4/333) |
1 entry |
ENSG00000196588 |
|
ependymoma |
sequence_alteration |
2.174% (1/46) |
1 entry |
ENSG00000196588 |
|
acute myeloid leukemia |
frameshift_variant |
1.544% (14/907) |
1 entry |
ENSG00000196588 |
|
small cell lung carcinoma |
sequence_alteration |
0.3106% (1/322) |
1 entry |
ENSG00000196588 |
|
ganglioneuroblastoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000196588 |
|
non-small cell lung carcinoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000196588 |
|
oral squamous cell carcinoma |
conservative_inframe_deletion |
2.427% (5/206) |
1 entry |
ENSG00000196588 |
|
basal cell carcinoma |
sequence_alteration |
1.724% (1/58) |
1 entry |
ENSG00000196588 |
|
acute myeloid leukemia |
missense_variant |
1.544% (14/907) |
1 entry |